A prospective study on optimizing arrhythmia management in a tertiary care hospital

Ahimahemmanuel; Thabit Ahmed; Balakeswa Ramaiah

doi:10.18203/2319-2003.ijbcp20250899

Authors

Ahimahemmanuel Department of Pharmacy Practice, Karnataka College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bengaluru, Karnataka, India
Thabit Ahmed Department of Cardiology, Karnataka College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bengaluru, Karnataka, India
Balakeswa Ramaiah Department of Pharmacy Practice, Karnataka College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20250899

Keywords:

Arrhythmia, Atrial fibrillation, Stroke risk, Antiarrhythmic drugs, Anticoagulants, Prospective study

Abstract

Background: Arrhythmias, particularly atrial fibrillation (AF), significantly contribute to morbidity and mortality, especially in older adults. Effective management is essential to reducing stroke risk and improving outcomes. However, real-world treatment often deviates from guidelines, raising concerns about care consistency. This study aims to identify prevalent arrhythmias, assess stroke risk, examine the relationship between arrhythmias and age, and analyze prescription patterns of antiarrhythmic drugs (AADs) and anticoagulants in a tertiary care setting.

Methods: A prospective observational study was conducted with 50 patients diagnosed with arrhythmias. Data were collected through structured interviews using the arrhythmia-specific questionnaire in tachycardia and arrhythmia (ASTA) and medical records. Prescription patterns were analyzed using the Vaughan-Williams classification system.

Results: Atrial fibrillation with a rapid ventricular rate (AF with FVR) was the most common arrhythmia (44%). A significant 88% of patients had a severe stroke risk based on the CHAD₂ scale. Beta-blockers were the most prescribed AADs (45.59%), with amiodarone being the most common (30.88%). Heparin (37.68%) and aspirin (28.99%) were the leading anticoagulants.

Conclusions: The findings highlight AF’s high prevalence and associated stroke risk in older adults. While prescription patterns align with guidelines, the reliance on Amiodarone necessitates careful monitoring. Greater adherence to guideline-recommended newer oral anticoagulants (NOACs) is needed to optimize outcomes.

Metrics

Metrics Loading ...

References

Chiang CE, Goethals M, O'Neill JO, Naditch-Brûlé L, Brette S, Gamra H, et al; RealiseAF survey investigators. Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF. Europace. 2013;15(12):1733-40. DOI: https://doi.org/10.1093/europace/eut204

Martin RIR, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: Meta-analysis ofrandomised controlled trials. Heart. 2014;100(19):1506-10. DOI: https://doi.org/10.1136/heartjnl-2014-305482

Abo-Salem E, Fowler JC, Attari M, Cox CD, Perez-Verdia A, Panikkath R, et al. Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther. 2014;32(1):19-25. DOI: https://doi.org/10.1111/1755-5922.12054

Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail. 2015;17(9):848-74. DOI: https://doi.org/10.1002/ejhf.338

Lahtela HM, Kiviniemi TO, Puurunen MK, Schlitt A, Rubboli A, Ylitalo A, et al. Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. PLoS One. 2015;10(6):e0128492. DOI: https://doi.org/10.1371/journal.pone.0128492

Behr ER, Roden D. Drug-induced arrhythmia: Pharmacogenomic prescribing? Eur Heart J. 2013;34(2):89-95. DOI: https://doi.org/10.1093/eurheartj/ehs351

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. DOI: https://doi.org/10.5603/KP.2016.0172

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104-32. DOI: https://doi.org/10.1161/CIR.0000000000000665

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI: https://doi.org/10.1056/NEJMoa1107039